臨床整形外科48巻7号

2013年07月発行

誌上シンポジウム 転移性骨腫瘍―治療の進歩

転移性骨腫瘍の薬物療法

著者： 高橋俊二¹

所属機関： ¹がん研究会有明病院化学療法部

ページ範囲：P.657 - P.661

文献概要

　最近，がんの骨転移治療の重要性が認識されるようになってきた．骨に転移した癌は，生命予後に大きな影響を及ぼさないが，骨関連事象(skeletal-related events，SRE)により患者のQOLを著しく低下させる．これに対してビスホスホネート，抗RANKL抗体デノスマブなどの破骨細胞を抑制する骨特異的薬剤が開発され，これらがSREを低下させることが確立されており，骨転移患者のQOL改善に寄与している．さらに新たな骨特異的薬剤の開発が進行している．

参考文献

1) Gnant M, Mlineritsch B, Schippinger W, et al:Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009

2) Henry DH, Costa L, Goldwasser F, et al:Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132, 2011　doi:10.1200/JCO.2010.31.3304.

3) Kohno N, Aogi K, Minami H, et al:Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321, 2005

4) Lipton A, Fizazi K, Stopeck AT, et al:Superiority of denosumab to zoledronic acid for prevention of skeletal-related events:A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082-3092, 2012

5) Ono K, Kamiya S, Akatsu T, et al:Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC. Bone 39:27-34, 2006

6) Saylor PJ, Lee RJ, Smith MR:Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 29:3705-3714, 2011

7) Smith MR, Saad F, Coleman R, et al:Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer:results of a phase 3, randomised, placebo-controlled trial. Lancet 379 (9810):39-46, 2012　doi:10.1016/S0140-6736 (11) 61226-9.

8) Stopeck AT, Lipton A, Body JJ, et al:Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010　doi:10.1200/JCO.2010.29.7101.

9) Storto G, Klain M, Paone G, et al:Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35-41, 2006

10) Takahashi S, Miyazaki M, Okamoto I, et al:Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. Cancer Sci 102:2058-2064, 2011

11) Yoneda T,Hiraga T:Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328:679-687, 2005

12) Yoneda T, Hagino H, Sugimoto T, et al:Bisphosphonate-related osteonecrosis of the jaw:position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365-383, 2010